metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus Standard of Care (SoC)
	pembrolizumab (2mg/kg)
	KEYNOTE-002 (2 mg/kg), 2015 Lancet Oncol. 2015; 16:908-18 Eur. J. Cancer 2017; 86:37-45 Eur. J. Cancer 2016; 67:46-54 Eur J Cancer 2020 Dec 23;144:182-191. NCT01704287	RCT	mML - L2 - all population	pembrolizumab	ICC (carboplatin plus paclitaxel, dacarbazine, paclitaxel alone or oral temozolomid)	unresectable stage III or stage IV melanoma not amenable to local therapy; confirmed disease progression14 within 24 weeks of the last ipilimumab dose	180 / 179	some concern	conclusif	inconclusive 14 % decrease in deaths (OS) (PE) demonstrated 43 % decrease in progression or deaths (PFS) (PE)